Literature DB >> 2087255

Characterisation and autoradiographic localisation of 5-HT3 receptor recognition sites identified with [3H]-(S)-zacopride in the forebrain of the rat.

J M Barnes1, N M Barnes, S Champaneria, B Costall, R J Naylor.   

Abstract

The pharmacological characterisation and topographical distribution of [3H]-(S)-zacopride recognition sites in the forebrain of the rat was studied using homogenate and autoradiographic radioligand binding techniques. [3H]-(S)-Zacopride labelled a single, saturable, specific binding site (defined by 10.0 microM granisetron) in homogenates prepared from the entorhinal cortex of the rat (pKD = 9.51 +/- 0.08; Bmax = 104 +/- 7 fmol mg-1 protein; mean +/- SEM, n = 8). Pharmacological characterisation of the recognition site, within the entorhinal cortex, suggested that [3H]-(S)-zacopride selectively labelled the recognition site of the 5-HT3 receptor. Specific binding of [3H]-(S)-zacopride (defined by 1.0 microM granisetron) was differentially distributed throughout the forebrain of the rat; highest densities were located within sub-nuclei of the amygdala (cortical amygdaloid nucleus, amygdalohippocampal area, posterior medial cortical amygdaloid nucleus, posterior lateral amygdaloid nucleus), cortical areas (primary olfactory cortex, entorhinal cortex) and hippocampus. Non-specific binding was distributed homogeneously, although lower in myelinated structures. It is concluded that [3H]-(S)-zacopride selectively labels 5-HT3 receptor recognition sites within the forebrain of the rat; the topographical distribution of these sites, within the limbic nuclei, is consistent with the behavioural actions in animal models of the selective 5-HT3 receptor antagonists.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2087255     DOI: 10.1016/0028-3908(90)90110-d

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  28 in total

1.  Effect of the 5-HT3 receptor antagonists, MDL72222 and ondansetron on morphine place conditioning.

Authors:  G A Higgins; N Joharchi; P Nguyen; E M Sellers
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  5-HT3 receptor antagonists ameliorate fatigue: so much potential, so little knowledge!

Authors:  N M Barnes
Journal:  Gut       Date:  2005-08       Impact factor: 23.059

3.  Evidence that the amygdala is involved in the disinhibitory effects of 5-HT3 receptor antagonists.

Authors:  G A Higgins; B J Jones; N R Oakley; M B Tyers
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

4.  A novel subpopulation of 5-HT type 3A receptor subunit immunoreactive interneurons in the rat basolateral amygdala.

Authors:  F Mascagni; A J McDonald
Journal:  Neuroscience       Date:  2006-12-05       Impact factor: 3.590

Review 5.  The central 5-HT3 receptor in CNS disorders.

Authors:  F E Bloom; M Morales
Journal:  Neurochem Res       Date:  1998-05       Impact factor: 3.996

6.  Serotonergic modulation of Neural activities in the entorhinal cortex.

Authors:  Saobo Lei
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2012-12-26

7.  Improvements in hippocampal-dependent learning and decremental attention in 5-HT(3) receptor overexpressing mice.

Authors:  Amber V Harrell; Andrea M Allan
Journal:  Learn Mem       Date:  2003 Sep-Oct       Impact factor: 2.460

8.  Possible antidepressant dihydroergosine preferentially binds to 5-HT1B receptor sites in the rat hippocampus.

Authors:  D Muck-Seler; D Pericić
Journal:  J Neural Transm Gen Sect       Date:  1993

9.  Differential modulation of extracellular levels of 5-hydroxytryptamine in the rat frontal cortex by (R)- and (S)-zacopride.

Authors:  N M Barnes; C H Cheng; B Costall; J Ge; R J Naylor
Journal:  Br J Pharmacol       Date:  1992-09       Impact factor: 8.739

Review 10.  The 5-HT3 receptor--the relationship between structure and function.

Authors:  Nicholas M Barnes; Tim G Hales; Sarah C R Lummis; John A Peters
Journal:  Neuropharmacology       Date:  2008-08-12       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.